Please assess the completion status of the following clinical trial:

Trial Title: Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- Subject has been diagnosed with primary ITP according to the American Society of Hematology (ASH) guidelines (George et al, 1996) and previously received only 1st line therapies.~First line therapy is defined as corticosteroids, immunoglobulin G (IVIG), anti-D and vinca alkaloids (used for the treatment of ITP related thrombocytopenia only). A platelet transfusion at any time during the six month period since the original diagnosis would not exclude the subject from study participation~* Initial diagnosis of primary ITP within 6 months of enrollment~* Age ≥ 18 years at screening~* A single platelet count ≤ 30 x 10⁹/L at any time during the screening period~* Subject or subject's legally acceptable representative has provided informed consent~Exclusion Criteria:~* Known history of a bone marrow stem cell disorder~* Surgical resection of the spleen~* Subject has a history of cancer or current malignancy other than basal cell carcinoma or cervical cancer in-situ with active treatment or disease within 5 years of screening~* Known history of congenital thrombocytopenia~* Known history of hepatitis B, hepatitis C, or human immunodeficiency virus~* Positive H. pylori by urea breath test or stool antigen test at screening~* Known history of systemic lupus erythematosus, Evans syndrome, or autoimmune neutropenia~* Known history of antiphospholipid antibody syndrome or positive for lupus anticoagulant~* Known history of disseminated intravascular coagulation, hemolytic uremic syndrome, or thrombotic thrombocytopenic purpura~* Previous history of recurrent venous thromboembolism or thrombotic events or an occurrence within 5 years of enrollment.~* Previous use of romiplostim, pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), eltrombopag, recombinant human thrombopoietin (rHuTPO) or any platelet producing agent~* Rituximab (for any indication) or mercaptopurine (6-MP) or anticipated use during the time of the proposed study~* All hematopoietic growth factors including interleukin-11 (IL-11) (oprelvekin) within 4 weeks before the screening visit~* Alkylating agents use at any time before or during the screening visit or anticipated during the time of the proposed study~* Known hypersensitivity to any recombinant E. coli-derived product (eg, Infergen, Neupogen, Somatropin, and Actimmune)~* Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational agent(s)~* Subject will have any other investigational procedures performed while enrolled in this clinical study~* Subject is pregnant or breast feeding, or planning to become pregnant within 5 weeks after the end of treatment~* Female subject of child bearing potential is not willing to use, in combination with her partner, highly effective contraception during treatment and for 4 weeks after the end of treatment~* Subject has previously enrolled into a romiplostim study~* Subject will not be available for protocol required study visits, to the best of the subject's and investigator's knowledge~* Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Romiplostim (Type: EXPERIMENTAL): Participants received romiplostim administered weekly by subcutaneous injection during the 12-month treatment period. The starting dose was 1 μg/kg with weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L.

Based on this trial design, predict the completion outcome and termination type (if applicable).